Emmanuel Katsanis, M.D.
Professor, Pediatrics, Pathology and Immunobiology
Louise Thomas Chair in Pediatric Cancer Research
Head, Division of Pediatric Hematology/Oncology

✉ University of Arizona
Department of Pediatrics
1501 N. Campbell Ave.
PO Box 245073
Tucson, Arizona 85724

☎ 520-626-4851

katsanis@peds.arizona.edu

EDUCATION

Medical School: National University of Athens, Athens, Greece, 1974-1980
Post Doctoral Research Associate, McGill University, Montreal, Canada, 1981-82
Internship: McGill University, Montreal, Canada, 1982-1983
Residency: Pediatrics, University of Ottawa, Ottawa, Canada, 1983-1987
Fellowship: Hematology/Oncology, University of Minnesota, Minneapolis, MN, 1987-1990
Post Doctoral Research Associate: University of Minnesota, Minneapolis, MN, 1990-1991

PROFESSIONAL POSITIONS

University of Minnesota, Medical School, Minneapolis, MN

Instructor of Pediatrics, 1991-1993
Assistant Professor of Pediatrics, 1993-1997

University of Arizona, College of Medicine, Tucson, AZ

Assistant Professor of Pediatrics, 1997-1998
Associate Professor of Pediatrics, 1998-2004
Associate Professor of Pathology, 1999-2004
Professor of Pediatrics, 2004-present
Professor of Pathology, 2004-present
Interim Head, Division of Pediatric Hematology/Oncology/BMT, 2004-2005
Head, Division of Pediatric Hematology/Oncology/BMT, 2005-present
Louise Thomas Endowed Chair in Pediatric Cancer Research, 2005-present
Professor of Immunobiology, 2007-present
Director, M.D.-Ph.D. Program, College of Medicine, 2010-present
Associate Chair for Research, Department of Pediatrics, 2011-present

CERTIFICATION

Educational Commission for Foreign Medical Graduates, ECFMG, 1980
Medical Council of Canada Evaluating Examination, MCCEE, 1981
Licentiate of the Medical Council of Canada, LMCC, 1983
Federation Licensing Examination, FLEX, 1986
Royal College of Physicians and Surgeons of Canada, Pediatrics, FRCPC, 1987
American Board of Pediatrics, Pediatrics, 1987
American Board of Pediatrics, Pediatric Hematology-Oncology, 1990
American Board of Pediatrics, Pediatric Hematology-Oncology, re-certification, 1997
American Board of Pediatrics, Pediatric Hematology-Oncology, re-certification, 2002

LICENSURE

Medical Association of Athens, Greece, 1981-83
College of Physicians and Surgeons of Ontario, #53061, 1983-96
State of Minnesota Medical License, #31044, 1987-97
State of Arizona Medical License, #25119, 1997-present

HONORS & AWARDS

Gordon E. Richard Award, Canadian Cancer Society Fellowship, 1986-1987
Award for Best Research Presentation by a Pediatric Resident, University of Ottawa, 1987
Wyeth Award for Excellence Achieved in Research, University of Ottawa, 1987
Outstanding Pediatric Fellow Award, University of Minnesota, 1988
Variety Club Fellowship, 1989-1990
Fellowship Award, Medical Research Council of Canada, 1989-1991
First Place Award, University of Minnesota Pediatric Fellows' Research Symposium, 1990
Irvine McQuarrie Research Scholar Award, 1992-1994
Young Investigator Award, American Society of Pediatric Hematology/Oncology, 1992
Clinical Oncology Career Development Award, American Cancer Society, 1993-1996
America's Top Pediatricians (Consumers' Research Council of America), 2004-2006
America's Top Oncologists (Consumers' Research Council of America), 2007-2010
Louise Thomas Endowed Chair in Pediatric Cancer Research, 2005-present
Leading Edge Researcher Award, University of Arizona, 2009

SCIENTIFIC ACTIVITIES

Faculty Member

University of Minnesota Cancer Center, 1994-1997
University of Minnesota Center for Immunology, 1995-1997
University of Arizona Cancer Center, 1997-present
University of Arizona Steele Children's Research Center, 1997-present
University of Arizona Interdisciplinary Graduate Program in Cancer Biology, 1998-present
University of Arizona Graduate Program in Immunobiology, 1999-present
University of Arizona BIO5 Institute, 2005-present

NIH Study Sections/Site Visits

NIH/NCI Program Project Site Visit Committee, Children's Hospital Los Angeles, USC, 1998
NIH/NCI Scientific Review Committee D, Clinical Research Studies, 1999
NIH/NCI Program Project Site Visit Committee, Rush University Medical Center, 2003
NIH/NCI Special Emphasis Panel/Approaches in Cancer Therapeutics, 2005
NIH/NCI Cancer Immunopathology and Immunotherapy Study Section, 2006
NIH/NCI Special Emphasis Panel/Cancer Therapy (Onc-B), 2006
NIH/NCI Cancer Immunopathology and Immunotherapy Study Section, Jan-2008
NIH/NCI Cancer Immunopathology and Immunotherapy Study Section, Oct-2008
NIH/NCI Clinical Oncology Study Section, Feb-2009
NIH/NCI Clinical Oncology Study Section, May-2009
NIH/NCI RFA OD-09-003 Challenge Grants Panel 10, June-2009
NIH/NCI Cancer Immunopathology and Immunotherapy Study Section, Sep-2009
NIH/NCI LRP OD09-109 Pediatric L40 A2, May-2010
NIH/NCI ZRG1 OTC-Y (02)-Cancer Therapeutics, Dec-2010
NIH/NCI Intramural Program Site Visit Committee, Pediatric Oncology Branch, May 2011
NIH/NCI Clinical Oncology Study Section, Chartered Member 2010-2014

Other Study Sections/Grant Reviews

American Cancer Society, Scientific Advisory Committee on Immunology, 1993
Manitoba Health Research Council, 1995
University of Manitoba Health Sciences Centre Foundation, 1995
Children's Hospital of Winnipeg Research Foundation, 1995
Children's Hospital of Eastern Ontario Research Institute, 1996
University of Manitoba Health Sciences Centre Foundation, 1996
American Cancer Society, Peer Review Committee on Cancer Immunology, 1997
Miami Children's' Hospital Research Institute, 2004
Italian Association for Cancer Research, 2004
Dept. of Defense (DOD) Chronic Myelogenous Leukemia Research Program (CMLRP), 2004
National Medical Research Council of Singapore, 2004
Italian Association for Cancer Research (preferred reviewers program), 2009-present
Greek Ministry for Education (Grant proposal review), 2011-present

Journal Editorial Boards

HAEMA, 2005-present
Cancer Immunology Immunotherapy, 2007-present
International Journal of Oncology, 2008-present
International Journal of Pediatrics, 2009-present

Journal Reviewer

Biology of Blood and Marrow Transplantation
Blood
Cancer Gene Therapy
Cancer Research
Cellular Immunology
Hospital Physician
European Journal of Immunology
Immunobiology
Immunological Investigations
International Immunopharmacology
International Journal of Cancer
Journal of Cellular Biochemistry
Journal of Immunology
Journal of Immunotherapy
Journal of Leukocyte Biology
Journal of Pediatrics
Journal of Pharmacology and Experimental Therapeutics
Journal of the National Cancer Institute
Leukemia
Nature Medicine
Neuro-Oncology
Oncogene
Transplantation

Scientific Conferences

Session Chairperson, International Society for Experimental Hematology Meeting, 1994

Memberships in Professional Societies

Fellow of the Royal College of Physicians and Surgeons of Canada, 1987-2009
American Association for Cancer Research, 1989- present
International Society for Biological Therapy of Cancer, 1992- present
American Association of Immunologists, 1995- present
American Society of Hematology, 1997- present
Children's Oncology Group, 2000- present
European Society for Cancer Immunology and Immunotherapy, 2006- present
World Hellenic Bioscientific Association, USA, 2006- present
American Society of Pediatric Hematology/Oncology, 2008- present
American Society for Blood and Marrow Transplantation, 2010- present
Pediatric Blood and Marrow Transplant Consortium, 2010- present

PUBLICATIONS (1774 citations, h-index 25; Thomson-Reuters, ISI Web of Science)

1. Tolis G, Montes J, Katsanis E, Bertrand G. Aspects of prolactin pathophysiology in relation to prolactin secreting adenomas. **Period Biol, 1983** 85(suppl 1): 29-36.
2. Katsanis E, McLaine PN. Wegener granulomatosis. **J Pediatr 1986** May;108(5 Pt 1):792-3. PMID: 3701531
3. Katsanis E, Hsu E, Luke KH, McKee JA. Systemic lupus erythematosus and sickle hemoglobinopathies: a report of two cases and review of the literature. **Am J Hematol 1987** Jun;25(2):211-4. PMID: 3605068
4. Katsanis E, Luke KH, Hsu E, Yates JR. Hemoglobin E: a common hemoglobinopathy among children of Southeast Asian origin. **CMAJ 1987** Jul 1;137(1):39-42. PMID: 3594333
5. Katsanis E, Luke KH, Hsu E, Carpenter BF, Mantynen PR. Neutrophilic eccrine hidradenitis in acute myelomonocytic leukemia. **Am J Pediatr Hematol Oncol 1987** Fall;9(3):204-8. PMID: 3479026
6. Katsanis E, Luke KH, Hsu E, Li M, Lillicrap D. Prevalence and significance of mild bleeding disorders in children with recurrent epistaxis. **J Pediatr 1988** Jul;113(1 Pt 1):73-6. PMID: 3385532
7. Kempe A., Hall C.B., MacDonald N.E., Foye H.R., Woodin K.A., Cohen H.J., Lewis E.D., Gullace M., Gala C.L., Dulberg C.S., Katsanis E. Influenza in children with cancer. **J of Pediatr 1989** 115: 33-39.
8. Katsanis E, Ramsay NK. Treatment of acquired severe aplastic anemia. **Am J Pediatr Hematol Oncol 1989** Fall;11(3):360-7. PMID: 2675662
9. Katsanis E, Malone B, Smith C. Recurrent epistaxis. **Pediatr Update 1990** Vol. 10, No. 12
10. Anderson PM, Katsanis E, Leonard AS, Schow D, Loeffler CM, Goldstein MB, Ochoa AC. Increased local antitumor effects of interleukin 2 liposomes in mice with MCA-106 sarcoma pulmonary metastases. **Cancer Res 1990** Mar 15;50(6):1853-6. PMID: 2306737
11. Katsanis E, Shapiro RS, Robison LL, Haake RJ, Kim T, Pescovitz OH, Ramsay NK. Thyroid dysfunction following bone marrow transplantation: long-term follow-up of 80 pediatric patients. **Bone Marrow Transplant 1990** May;5(5):335-40. PMID: 2350628
12. Katsanis E, Bausero MA, Ochoa AC, Loeffler CM, Blazar BR, Leonard AS, Anderson PM. Importance in timing of cyclophosphamide on the enhancement of interleukin-2-induced cytolysis. **Cancer Immunol Immunother 1991** 34(2):74-8. PMID: 1760819
13. Loeffler CM, Platt JL, Anderson PM, Katsanis E, Ochoa JB, Urba WJ, Longo DL, Leonard AS, Ochoa AC. Antitumor effects of interleukin 2 liposomes and anti-CD3-stimulated T-cells against murine MCA-38 hepatic metastasis. **Cancer Res 1991** Apr 15;51(8):2127-32. PMID: 1826232
14. Katsanis E, Anderson PM, Filipovich AH, Hasz DE, Rich ML, Loeffler CM, Ochoa AC, Weisdorf DJ. Proliferation and cytolytic function of anti-CD3 + interleukin-2 stimulated peripheral blood mononuclear cells following bone marrow transplantation. **Blood 1991** Sep 1;78(5):1286-91. PMID: 1831682
15. Sencer SF, Rich ML, Katsanis E, Ochoa AC, Anderson PM. Anti-tumor vaccine adjuvant effects of IL-2 liposomes in mice immunized against MCA-102 sarcoma. **Eur Cytokine Netw 1991** Nov-Dec;2(5):311-8. PMID: 1804322

16. Anderson PM, Katsanis E, Sencer SF, Hasz D, Ochoa AC, Bostrom B. Depot characteristics and biodistribution of interleukin-2 liposomes: importance of route of administration. J **Immunother 1992** Jul;12(1):19-31. PMID: 1637781

17. Katsanis E, Orchard PJ, Bausero MA, Gorden KB, McIvor RS, Blazar BR. Interleukin-2 gene transfer into murine neuroblastoma decreases tumorigenicity and enhances systemic immunity causing regression of preestablished retroperitoneal tumors. **J Immunother 1994** Feb;15(2):81-90. PMID: 8136949

18. Katsanis E, Bausero MA, Xu H, Orchard PJ, Xu Z, McIvor RS, Brian AA, Blazar BR. Transfection of the mouse ICAM-1 gene into murine neuroblastoma enhances susceptibility to lysis, reduces in vivo tumorigenicity and decreases ICAM-2-dependent killing. **Cancer Immunol Immunother 1994** Feb;38(2):135-41. PMID: 7905790

19. Katsanis E, Blazar BR, Bausero MA, Gunther R, Anderson PM. Retroperitoneal inoculation of murine neuroblastoma results in a reliable model for evaluation of the antitumor immune response. **J Pediatr Surg 1994** Apr;29(4):538-42. PMID: 8014811

20. Katsanis E, Weisdorf DJ, Xu Z, Dancisak BB, Halet ML, Blazar BR. Infusions of interleukin-1 alpha after autologous transplantation for Hodgkin's disease and non-Hodgkin's lymphoma induce effector cells with antilymphoma cytolytic activity. **J Clin Immunol 1994** May;14(3):205-11. PMID: 7929695

21. Weisdorf D, Katsanis E, Verfaillie C, Ramsay NK, Haake R, Garrison L, Blazar BR. Interleukin-1 alpha administered after autologous transplantation: a phase I/II clinical trial. **Blood 1994** Sep 15;84(6):2044-9. PMID: 7915916

22. Katsanis E, Xu Z, Anderson PM, Dancisak BB, Bausero MA, Weisdorf DJ, Blazar BR, Ochoa AC. Short-term ex vivo activation of splenocytes with anti-CD3 plus IL-2 and infusion post-BMT into mice results in in vivo expansion of effector cells with potent anti-lymphoma activity. **Bone Marrow Transplant 1994** Oct;14(4):563-72. PMID: 7858530

23. Katsanis E, Xu Z, Bausero MA, Dancisak BB, Gorden KB, Davis G, Gray GS, Orchard PJ, Blazar BR. B7-1 expression decreases tumorigenicity and induces partial systemic immunity to murine neuroblastoma deficient in major histocompatibility complex and costimulatory molecules. **Cancer Gene Ther 1995** Mar;2(1):39-46. PMID: 7542553

24. Bausero MA, Panoskaltsis-Mortari A, Blazar BR, Katsanis E. Effective immunization against neuroblastoma using double-transduced tumor cells secreting GM-CSF and interferon-gamma. **J Immunother 1996** Mar;19(2):113-24. PMID: 8732694

25. Katsanis E, Bausero MA, Panoskaltsis-Mortari A, Dancisak BB, Xu Z, Orchard PJ, Davis CG, Blazar BR. Irradiation of singly and doubly transduced murine neuroblastoma cells expressing B7-1 and producing interferon-gamma reduces their capacity to induce systemic immunity. **Cancer Gene Ther 1996** Mar-Apr;3(2):75-82. PMID: 8729905

26. Orchard PJ, Katsanis E, Boyer M, May C, McIvor RS, Blazar BR. Interleukin-2 secretion by transduced and unselected BDL-2 lymphoma results in increased survival in mice with previously established disseminated disease. **Cancer Biother Radiopharm 1996** Apr;11(2):155-64. PMID: 10851532

27. Katsanis E, Xu Z, Panoskaltsis-Mortari A, Weisdorf DJ, Widmer MB, Blazar BR. IL-15 administration following syngeneic bone marrow transplantation prolongs survival of lymphoma bearing mice. **Transplantation 1996** Sep 27;62(6):872-5. PMID: 8824494

28. Saltzman DA, Katsanis E, Heise CP, Hasz DE, Vigdorovich V, Kelly SM, Curtiss R 3rd, Leonard AS, Anderson PM. Antitumor mechanisms of attenuated Salmonella typhimurium containing the gene for human interleukin-2: a novel antitumor agent? **J Pediatr Surg 1997** Feb;32(2):301-6. PMID: 9044141

29. Davies SM, Wagner JE, Shu XO, Blazar BR, Katsanis E, Orchard PJ, Kersey JH, Dusenbery KE, Weisdorf DJ, McGlave PB, Ramsay NK. Unrelated donor bone marrow transplantation for children with acute leukemia. **J Clin Oncol 1997** Feb;15(2):557-65. PMID: 9053477

30. Xu Z, Katsanis E. Improved immunostimulatory function of bone marrow derived macrophages transduced with the granulocyte-macrophage colony stimulating factor gene. **Cancer Biother Radiopharm 1997** Feb; 12(1):27-36. PMID: 10851444

31. Saltzman DA, Katsanis E, Heise CP, Hasz DE, Kelly SM, Curtiss R 3rd, Leonard AS, Anderson PM. Patterns of hepatic and splenic colonization by an attenuated strain of Salmonella typhimurium containing the gene for human interleukin-2: a novel anti-tumor agent. **Cancer Biother Radiopharm 1997** Feb;12(1):37-45. PMID: 10851445

32. Davies SM, Wagner JE, Defor T, Blazar BR, Katsanis E, Kersey JH, Orchard PJ, McGlave PB, Weisdorf DJ, Ramsay NK. Unrelated donor bone marrow transplantation for children and adolescents with aplastic anaemia or myelodysplasia. **Br J Haematol 1997** Mar;96(4):749-56. PMID: 9074418

33. Khanna C, Anderson PM, Hasz DE, Katsanis E, Neville M, Klausner JS. Interleukin-2 liposome inhalation therapy is safe and effective for dogs with spontaneous pulmonary metastases. **Cancer 1997** Apr 1;79(7):1409-21. PMID: 9083164

34. Miller JS, Tessmer-Tuck J, Pierson BA, Weisdorf D, McGlave P, Blazar BR, Katsanis E, Verfaillie C, Lebkowski J, Radford J Jr, Burns LJ. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity. **Biol Blood Marrow Transplant 1997** Apr;3(1):34-44. PMID: 9209739

35. Boyer MW, Vallera DA, Taylor PA, Gray GS, Katsanis E, Gorden K, Orchard PJ, Blazar BR. The role of B7 costimulation by murine acute myeloid leukemia in the generation and function of a CD8+ T-cell line with potent in vivo graft-versus-leukemia properties. **Blood 1997** May 1;89(9):3477-85. PMID: 9129056

36. Khanna C, Waldrep JC, Anderson PM, Weischelbaum RW, Hasz DE, Katsanis E, Klausner JS. Nebulized interleukin 2 liposomes: aerosol characteristics and biodistribution. **J Pharm Pharmacol 1997** Oct;49(10):960-71. PMID: 9364403

37. Katsanis E. Immunobiology and biologic therapy of neuroblastoma. In Bertino J.R. ed. **Encyclopedia of Cancer 1997**, 1st ed., Academic Press, San Diego CA. 1142-1154.

38. Katsanis E, Weisdorf DJ, Miller JS. Activated peripheral blood mononuclear cells from patients receiving subcutaneous interleukin-2 following autologous stem cell transplantation prolong survival of SCID mice bearing human lymphoma. **Bone Marrow Transplant 1998** Jul;22(2):185-91. PMID: 9707028

39. Smith DF, Whitesell L, Katsanis E. Molecular chaperones: biology and prospects for pharmacological intervention. **Pharmacol Rev 1998** Dec;50(4):493-514. PMID: 9860803

40. Perentesis J, Katsanis E, DeFor T, Neglia J, Ramsay N. Autologous stem cell transplantation for high-risk pediatric solid tumors. **Bone Marrow Transplant 1999** Sep;24(6):609-15. PMID: 10490725

41. Graner M, Raymond A, Romney D, He L, Whitesell L, Katsanis E. Immunoprotective activities of multiple chaperone proteins isolated from murine B-cell leukemia/lymphoma. **Clin Cancer Res 2000** Mar;6(3):909-15. PMID: 10741715

42. Yorgin PD, Hartson SD, Fellah AM, Scroggins BT, Huang W, Katsanis E, Couchman JM, Matts RL, Whitesell L. Effects of geldanamycin, a heat-shock protein 90-binding agent, on T cell function and T cell nonreceptor protein tyrosine kinases. **J Immunol 2000** Mar 15;164(6):2915-23. PMID: 10706677

43. Graner M, Raymond A, Akporiaye E, Katsanis E. Tumor-derived multiple chaperone enrichment by free-solution isoelectric focusing yields potent antitumor vaccines. **Cancer Immunol Immunother 2000** Nov;49(9):476-84. PMID: 11092614

44. McEarchern JA, Kobie JJ, Mack V, Wu RS, Meade-Tollin L, Arteaga CL, Dumont N, Besselsen D, Seftor E, Hendrix MJ, Katsanis E, Akporiaye ET. Invasion and metastasis of a mammary tumor involves TGF-beta signaling. **Int J Cancer 2001** Jan 1;91(1):76-82. PMID: 11149423

45. He L, Feng H, Raymond A, Kreeger M, Zeng Y, Graner M, Whitesell L, Katsanis E. Dendritic-cell-peptide immunization provides immunoprotection against bcr-abl-positive leukemia in mice. **Cancer Immunol Immunother 2001** Mar;50(1):31-40. PMID: 11315508

46. Feng H, Zeng Y, Whitesell L, Katsanis E. Stressed apoptotic tumor cells express heat shock proteins and elicit tumor-specific immunity. **Blood 2001** Jun 1;97(11):3505-12. PMID: 11369644

47. Feng H, Zeng Y, Graner MW, Katsanis E. Stressed apoptotic tumor cells stimulate dendritic cells and induce specific cytotoxic T cells. **Blood 2002** Dec 1;100(12):4108-15. Epub 2002 Jul 25. PMID: 12393401

48. Katsanis E, Whitesell L. Neuroblastoma. In Bertino J.R. ed. **Encyclopedia of Cancer 2002**, 2nd ed., Academic Press, San Diego CA. 315-321.

49. Feng H, Zeng Y, Graner MW, Likhacheva A, Katsanis E. Exogenous stress proteins enhance the immunogenicity of apoptotic tumor cells and stimulate antitumor immunity. **Blood 2003** Jan 1;101(1):245-52. Epub 2002 Aug 22. PMID: 12393411

50. Graner MW, Zeng Y, Feng H, Katsanis E. Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers. **Cancer Immunol Immunother 2003** Apr;52(4):226-34. Epub 2003 Feb 18. PMID: 12669247

51. Zeng Y, Feng H, Graner MW, Katsanis E. Tumor-derived, chaperone-rich cell lysate activates dendritic cells and elicits potent antitumor immunity. **Blood 2003** Jun 1;101(11):4485-91. Epub 2003 Feb 6. PMID: 12576309

52. Feng H, Zeng Y, Graner MW, Whitesell L, Katsanis E. Evidence for a Novel, Caspase-8-Independent, Fas Death Domain-Mediated Apoptotic Pathway. **J Biomed Biotechnol 2004** 2004(1):41-51. PMID: 15123887

53. Zeng Y, Graner MW, Feng H, Li G, Katsanis E. Imatinib mesylate effectively combines with chaperone-rich cell lysate-loaded dendritic cells to treat bcr-abl+ murine leukemia. **Int J Cancer 2004** Jun 10;110(2):251-9. PMID: 15069690

54. Graner MW, Likhacheva A, Davis J, Raymond A, Brandenberger J, Romanoski A, Thompson S, Akporiaye E, Katsanis E. Cargo from tumor-expressed albumin inhibits T-cell activation and responses. **Cancer Res 2004** Nov 1;64(21):8085-92. PMID: 15520220

55. Graner MW, Katsanis E. Chaperone proteins/Heat shock proteins as anticancer vaccines. In Morse M.A., Clay T.M., Lyerly H.K. ed. **Handbook of Cancer Vaccines 2004**, Humana Press, Totowa NJ. 297-316, .

56. Zeng Y, Graner MW, Thompson S, Marron M, Katsanis E. Induction of BCR-ABL-specific immunity following vaccination with chaperone-rich cell lysates derived from BCR-ABL+ tumor cells. **Blood 2005** Mar 1;105(5):2016-22. Epub 2004 Sep 16. PMID: 15374884

57. Ramanathapuram LV, Hahn T, Graner MW, Katsanis E, Akporiaye ET. Vesiculated alpha-tocopheryl succinate enhances the anti-tumor effect of dendritic cell vaccines. **Cancer Immunol Immunother 2006** Feb;55(2):166-77. Epub 2005 Jul 23. PMID: 16041582

58. Zeng Y, Graner MW, Katsanis E. Chaperone-rich cell lysates, immune activation and tumor vaccination. **Cancer Immunol Immunother 2006** Mar;55(3):329-38. Epub 2005 May 11. PMID: 15887013

59. Chen X, Zeng Y, Li G, Larmonier N, Graner MW, Katsanis E. Peritransplantation vaccination with chaperone-rich cell lysate induces antileukemia immunity. **Biol Blood Marrow Transplant 2006** Mar;12(3):275-83. PMID: 16503496

60. Larmonier N, Mérino D, Nicolas A, Cathelin D, Besson A, Bateman A, Solary E, Martin F, Katsanis E, Bonnotte B. Apoptotic, necrotic, or fused tumor cells: an equivalent source of antigen for dendritic cell loading. **Apoptosis 2006** Sep;11(9):1513-24. PMID: 16738802

61. Zeng Y, Chen X, Larmonier N, Larmonier C, Li G, Sepassi M, Marron M, Andreansky S, Katsanis E. Natural killer cells play a key role in the antitumor immunity generated by chaperone-rich cell lysate vaccination. **Int J Cancer 2006** Dec 1;119(11):2624-31. PMID: 16989012

62. Larmonier N, Marron M, Zeng Y, Cantrell J, Romanoski A, Sepassi M, Thompson S, Chen X, Andreansky S, Katsanis E. Tumor-derived CD4(+)CD25(+) regulatory T cell suppression of dendritic cell function involves TGF-beta and IL-10. **Cancer Immunol Immunother 2007** Jan;56(1):48-59. Epub 2006 Apr 13. PMID: 16612596

63. Chen X, Zhou B, Li M, Deng Q, Wu X, Le X, Wu C, Larmonier N, Zhang W, Zhang H, Wang H, Katsanis E. CD4(+)CD25(+)FoxP3(+) regulatory T cells suppress Mycobacterium tuberculosis immunity in patients with active disease. **Clin Immunol 2007** Apr;123(1):50-9. Epub 2007 Jan 17. PMID: 17234458

64. Li G, Zeng Y, Chen X, Larmonier N, Sepassi M, Graner MW, Andreansky S, Brewer MA, Katsanis E. Human ovarian tumour-derived chaperone-rich cell lysate (CRCL) elicits T cell responses in vitro. **Clin Exp Immunol 2007** Apr;148(1):136-45. PMID: 17349014

65. Kislin KL, Marron MT, Li G, Graner MW, Katsanis E. Chaperone-rich cell lysate embedded with BCR-ABL peptide demonstrates enhanced anti-tumor activity against a murine BCR-ABL positive leukemia. **FASEB J 2007** Jul;21(9):2173-84. Epub 2007 Feb 27. PMID: 17327358

66. Larmonier N, Cathelin D, Larmonier C, Nicolas A, Merino D, Janikashvili N, Audia S, Bateman A, Thompson J, Kottke T, Hartung T, Katsanis E, Vile R, Bonnotte B. The inhibition of TNF-alpha antitumoral properties by blocking antibodies promotes tumor growth in a rat model. **Exp Cell Res 2007** Jul 1;313(11):2345-55. Epub 2007 Mar 30. PMID: 17466973

67. Li G, Andreansky S, Helguera G, Sepassi M, Janikashvili N, Cantrell J, Lacasse CL, Larmonier N, Penichet ML, Katsanis E. A chaperone protein-enriched tumor cell lysate vaccine generates protective humoral immunity in a mouse breast cancer model. **Mol Cancer Ther. 2008** Mar;7(3):721-9. PMID: 18347157

68. Larmonier N, Cantrell J, Lacasse C, Li G, Janikashvili N, Situ E, Sepassi M, Andreansky S, Katsanis E. Chaperone-rich tumor cell lysate-mediated activation of antigen-presenting cells resists regulatory T cell suppression. **J Leukoc Biol 2008** Apr;83(4):1049-59. Epub 2008 Jan 3. PMID: 18174364

69. Bleifuss E, Bendz H, Sirch B, Thompson S, Brandl A, Milani V, Graner MW, Drexler I, Kuppner M, Katsanis E, Noessner E, Issels RD. Differential capacity of chaperone-rich lysates in cross-presenting human endogenous and exogenous melanoma differentiation antigens. **Int J Hyperthermia** 2008 Dec;24(8):623-37. PMID: 18608582

70. Larmonier N, Janikashvili N, LaCasse C, Larmonier C, Cantrell J, Situ E, Li G, Bonnotte B, Katsanis E. Imatinib mesylate suppresses CD4+CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABLnegative tumors. **J Immunol 2008** Nov 181:6955-63. PMID: 18981115

71. Larmonier N, Fraszczak J, Lakomy D, Bonnotte B, Katsanis E. Killer dendritic cells and their potential for cancer immunotherapy. **Cancer Immunol Immunother 2010** Jan 59(1):1-11. Epub 2009 Jul 18. PMID: 19618185

72. Janikashvili N., Larmonier N., Katsanis E. Personalized dendritic cell-based tumor immunotherapy. **Immunother 2010** Jan 2(1):57-68. PMID: 20161666

73. Fraszczak J., Trad M., Janikashvili N., Cathelin D., Lakomy D., Granci V., Morizot A., Audia S., Micheau O., Lagrost L., Katsanis E., Solary E., Larmonier N., Bonnotte B. Peroxynitrite-dependent killing of cancer cells and presentation of released tumor antigens by activated dendritic cells. **J Immunol 2010** Feb 15; 184(4):1876-84. Epub 2010 Jan 20. PMID: 20089706

74. Cantrell J., Larmonier C., Janikashvili N., Bustamante S., Fraszczak J., Herrell A., Lundeen T., LaCasse C., Situ E., Larmonier N., Katsanis E. Signaling pathways induced by a tumor-derived vaccine in antigen presenting cells.. **Immunobiology 2010** July 215(7):535-544 Epub 2009 Oct 30. PMID: 19880213

75. Janikashvili N., LaCasse C., Larmonier C.,Trad M., Herrell A., Bustamante S., Har-Noy M., Larmonier N., Katsanis E. Allogeneic effector/memory Th-1 cells impair FoxP3$^+$ regulatory T cells and synergize with chaperone-rich cell lysate vaccine to treat leukemia. **Blood** Epub 2010 Jan 20. PMID: 21123824

76. Lakomy D., Fraszczak J., Trad M., Janikashvili N., Audia S., Samson M., Ciudad M., Vinit J., Vergely C., Caillot D., Foucher P., Lagrost L., Katsanis E., Larmonier N., Bonnotte B. Cytotoxic dendritic cells generated from cancer patients (in revision)

77. Centuori S., Larmonier C., LaCasse C.J., Hanke N.T., Kartchner J., Janikashvili N., Trad M., Alizadeh D., Bonnotte B., Larmonier N., Katsanis E. Tumor-induced myeloid-derived suppressor cells impair the differentiation of CD4$^+$CD25$^+$FoxP3$^+$ regulatory T cells from naïve CD4$^+$CD25$^-$FoxP3$^-$ T lymphocytes (submitted)

78. Bravo R., Pelayo-Katsanis L.O, Shehab Z., Katsanis E. Impact of endemic coccidioidomycosis in the practice of pediatric oncology. (submitted)

ABSTRACTS

1. Katsanis E., Tolis G., Abou-Abdallah M. Male reproductive function in patients with hyperprolactinemia. Presented at the First International Symposium on Hyperprolactinemia and Reproduction, Mexico City, October 1981.
2. Katsanis E., Mercer S. Crohn's disease in children and adolescents. Presented at the Eastern Ontario Paediatric Association, Kingston, Ontario, May 1984.
3. Katsanis E., Luke K.H., Hsu E. Hemoglobinopathies in children from Southeast Asia. Presented at the Eastern Ontario Paediatric Association, Smiths Falls, Ontario, May 1985.
4. Katsanis E., Hsu E., McKee J.A. Association of sickle hemoglobinopathies with systemic lupus erythematosus. Presented at the Canadian Paediatric Society and the Canadian Society for Clinical Investigation, Vancouver, British Columbia, September 1985. Clin Invest Med 8(3):A174, 1985.
5. Katsanis E., Hsu E., Luke K.H. Isolated testicular relapse in acute lymphoblastic leukemia following bone marrow transplantation. Presented at the Royal College of Physicians and Surgeons of Canada and the Canadian Hematology Society, Vancouver, British Columbia, September 1985. Clin Invest Med 8(3):A122, 1985.
6. Katsanis E., Luke K. H., Hsu E., Yates J. Hemoglobin E: A frequently encountered disorder among Southeast Asian children in Canada. Presented at the Canadian Paediatric Society, Toronto, Ontario, September 1986. Clin Invest Med 9(3):A136, 1986.
7. Katsanis E., Luke K.H., D'Astous J., Hsu E., Jones H. Surgical synovectomy for severe arthropathy in two hemophilia A children with low titre inhibitors. Presented at the Royal College of Physicians and Surgeons of Canada and the Canadian Hematology Society, Toronto, Ontario, September 1986. Clin Invest Med 9(3):A81, 1986.
8. Katsanis E., Luke K.H., Hsu E., Li M., Lillicrap D. Recurrent epistaxis in childhood; when is hemostatic evaluation warranted. Presented at the Eastern Ontario Paediatric Association, Kingston, Ontario, June 1987.
9. Katsanis E., Luke K.H., Hsu E., Li M., Lillicrap D. The prevalence and significance of mild bleeding disorders in children with recurrent epistaxis. Pediatr Res 23(4):341A, 1988.
10. Luke K.H., Katsanis E., Hsu E. Bleeding disorders in children with recurrent epistaxis. Presented at the Joint Chinese-Canadian Pediatric Societies, Beijing, People's Republic of China, November 1988.
11. Katsanis E., Shapiro R.S., Robison T.H., Kim T.H., Haake R., Ramsay N.K.C. Long-term follow-up of thyroid function in 77 patients following bone marrow transplantation. Proc Am Soc Clin Oncol 8:17, 1989.
12. Katsanis E., Loeffler C.M., Ochoa A.C., Anderson P.M. Murine pharmacokinetic studies following free and liposomal interleukin-2 administration. Presented at the Pediatric Fellows' Research Symposium, University of Minnesota, Minneapolis, Minnesota, April 1989.
13. Loeffler C.M., Ochoa A.C., Katsanis E., Anderson P.M., Leonard, A.S. Immunotherapy of hepatic metastases of murine adenocarcinoma using IL-2 liposomes. Presented at the 7th International Congress of Immunology, Berlin, Federal Republic of Germany, July 1989.

14. Katsanis E., Shapiro R.S., Robison T.H., Haake R., Kim T.H., Pescovitz O.H., Ramsay N.K.C. Thyroid dysfunction following bone marrow transplantation. Presented at the Northwestern Pediatric Society, Rochester, Minnesota, September 1989.

15. Anderson P.M., Katsanis E., Rich M.L., Leonard A.S., Loeffler C.M., Ochoa A.C. Immunoadjuvant studies of IL-2 liposomes against cancer: Murine pharmacokinetic and antitumor efficacy studies using intracavitary routes of administration. Presented at the UCLA Symposia on Molecular and Cellular Biology, Park City, Utah, January, 1990. J Cell Biochem Suppl 14B:93, 1990.

16. Katsanis E., Ochoa A.C., Bausero M.A., Loeffler C.M., Anderson P.M. Combination therapy of C1300 murine neuroblastoma with IL-2 liposomes, anti-GD2 monoclonal antibody and cyclophosphamide. Presented at the UCLA Symposia on Molecular and Cellular Biology, Park City, Utah, January, 1990. J Cell Biochem Suppl 14B:97, 1990.

17. Katsanis E., Ochoa A.C., Bausero M.A., Loeffler C.M., Anderson P.M. Cyclophosphamide enhances LAK activity against neuro-2a murine neuroblastoma. Presented at the American Association for Cancer Research, Washington, D.C., May 1990. Proc Am Assoc Cancer Res 31:270, 1990.

18. Anderson P.M., Weisdorf D.J., Hasz D.E., Rich M.L., Ochoa A.C., Katsanis E. Bone marrow transplant patients have significantly enhanced cytolytic activity but inferior proliferation of peripheral blood mononuclear cells stimulated with anti-CD3 + interleukin-2. Presented at the American Association for Cancer Research, Washington, D.C., May 1990. Proc Am Assoc Cancer Res 31:269, 1990.

19. Katsanis E., Ochoa A.C., Bausero M.A., Anderson P.M. Effect of interleukin-2 and cyclophosphamide on the antitumor immune response against murine neuroblastoma. Presented at the American Society of Pediatric Hematology/Oncology, Chicago, Illinois, September 1990.

20. Anderson, P.M., Katsanis E., Hasz D., Weisdorf D. Development of specific T cell mediated anti-B lineage acute lymphoblastic leukemia cellular immunity using in vivo interleukin-2 after autologous bone marrow transplant. Presented at the American Society of Pediatric Hematology/Oncology, Chicago, Illinois, September 1990.

21. Weisdorf D.J., Anderson P.M., Katsanis E., Kersey J.H., Ramsay N.K.C. Interleukin-2 plus autologous marrow transplantation for acute lymphoblastic leukemia: In vivo activation of cytolytic lymphoid effectors. Presented at the American Society of Hematology, Boston, Massachusetts, December 1990. Blood 76(suppl 1):572a, 1990.

22. Anderson P.M., Hasz D.E., Rich M.L., Sencer S.F., Katsanis E., Loeffler C.M., Ochoa A.C. Studies of interleukin-2 liposomes, a cytokine formulation with depot characteristics and adjuvant properties. Presented at the American Society of Pediatric Hematology/Oncology, Chicago, Illinois, September 1991.

23. Katsanis E., Bausero M.A., Blazar B.R. Interferon-γ enhances lysis of murine neuroblastoma by upregulating tumor cell adhesion molecules. Presented at the American Association for Cancer Research, San Diego, California, May 1992. Proc Am Assoc Cancer Res 33:296, 1992.

24. Katsanis E., Orchard P.J., Bausero M.A., Gorden K.B., McIvor R.S., Blazar B.R. Retroviral vector mediated IL-2 gene transfer into murine neuroblastoma cells reduces their tumorigenicity. Presented at the American Society of Pediatric Hematology/Oncology, Chicago, Illinois, September 1992. Proc Am Soc Pediatr Hematol Oncol 1:12, 1992.

25. Weisdorf D.J., Katsanis E., Verfaillie C., Ramsay N.K.C., Garrison L., Blazar B.R. Interleukin-1a after autologous marrow transplantation for lymphoma/Hodgkin's disease: clinical and hemalologic effects.

Presented at the American Society of Hematology, Anaheim, California, December 1992. Blood 80(suppl 1):333a, 1992.

26. Katsanis E., Orchard P.J., Bausero M.A., Gorden K.B., McIvor R.S., Blazar B.R. Decreased tumorigenicity of murine neuroblastoma after retroviral vector mediated IL-2 gene transfer and expression. Presented at the Keystone Symposia on Molecular and Cellular Biology, Taos, New Mexico, March 1993. J Cell Biochem Suppl 17D:119, 1993.

27. Orchard P.J., Katsanis E., Gorden K.B., May C., McIvor R.S., Blazar B.R. Retroviral vector mediated gene transfer of IL-2 reduces tumorigenicity in murine lymphoma. Presented at the Keystone Symposia on Molecular and Cellular Biology, Taos, New Mexico, March 1993. J Cell Biochem Suppl 17D:120, 1993.

28. Katsanis E., Blazar B.R., Xu Z., Barrett B.A., Bausero M.A., Anderson P.M., Orchard P.J., Weisdorf D.J., Ochoa A.C. In vivo proliferation, distribution and anti-tumor effect of anti-CD3 activated splenocytes following syngeneic murine bone marrow transplantation. Presented at the American Association for Cancer Research, Orlando, Florida, May 1993. Proc Am Assoc Cancer Res 34:469, 1993.

29. Bausero M.A., Panoskaltsis-Mortari A., Xu Z., Blazar B.R., Katsanis E. Effective immunization against murine neuroblastoma using transduced tumor cells secreting GM-CSF and interferon-γ. Presented at the International Conference on Gene Therapy of Cancer, San Diego, California, November 1995. Cancer Gene Ther, 2: 309, 1995.

30. Katsanis E., Xu Z., Panoskaltsis-Mortari A., Hasz D.E., Weisdorf D.J., Widmer M.B., Blazar B.R. IL-15 administration following syngeneic murine bone marrow transplantation for lymphoma improves survival and has decreased toxicity when compared to IL-2. Presented at the American Society of Hematology, Seattle, Washington, December 1995. Blood 86(suppl 1):571a, 1995.

31. Saltzman D.A., Katsanis E., Heise C.P., Hasz D.E., Vigdorovich V., Curtiss R.E., Anderson P.M., Leonard A.S. Anti-tumor mechanisms of attenuated salmonella typhimurium containing the gene for human IL-2. Presented at the American Pediatric Surgical Association. San Diego, California, May 1996.

32. Saltzman D.A., Katsanis E., Heise C.P., Hasz D.E., Kelly S.M., Curtiss R.E., Anderson P.M., Leonard A.S. Hepatic and splenic colonization by an attenuated salmonella typhimurium strain containing the gene for human IL-2: A novel anti-tumor agent. Presented at the Surgical Infection Society, Milwaukee, Wisconsin, April 1996.

33. Miller J.S., Tuck J., Pierson B.A., Weisdorf D.J., McGlave P.B., Blazar B.R., Katsanis E., Verfaillie C., Lebkowski J., Radford J., Burns L. Low dose subcutaneous interleukin-2 after autologous BMT safely augments natural killer activity. Presented at the International Society of Experimental Hematology, New York City, New York, August 1996. Exp Hematol 24:1090, 1996.

34. Sanan A., LeBien TW., Katsanis E. Transduction of granulocyte-macrophage colony stimulating factor abolishes the tumorgenicity of the c6 rat glioma cell line. Presented at the Congress for Neurological Surgeons, Montreal, Quebec, October 1996. Neurosurgery 39:648, 1996.

35. Davies S.M., Wagner J.E., Defor T., Blazar B.R., Katsanis E., Kersey J.H., Orchard P.J., McGlave P.B., Weisdorf D.J., Ramsay N.K.C. Unrelated donor bone marrow transplantation for children and adolescents with aplastic anemia or myelodysplasia. Presented at the American Society of Hematology, Orlando, Florida, December 1996. Blood 88(suppl 1):267a, 1996.

36. Miller J.S., Tessmer-Tuck J., Pierson B.A., Weisdorf D.J., McGlave P.B., Blazar B.R., Katsanis E., Verfaillie C., Burns L. Subcutaneous IL-2 after autologous BMT expands NK cells in vivo but requires ex

vivo high-dose IL-2 for maximal activation. Presented at the American Society of Hematology, Orlando, Florida, December 1996. Blood 88(suppl 1):609a, 1996.

37. He L., Graner M., Katsanis E. Dendritic cells induce T cell responses against bcr/abl^{+} chronic myelogenous leukemia. Presented at the Keystone Symposia on Molecular and Cellular Biology, Cellular and Molecular Biology of Dendritic Cells, Santa Fe, New Mexico, March 1998.

38. Bulte J.W.M, Verkuyl J.M., Herynek V., Katsanis E., Brocke S., Holla M., Frank J.A. Magnetoimmunodetection of (transfected) ICAM-1 gene expression. Presented at the 6th International Society of Magnetic Resonance in Medicine (ISMRM) Conference, Sydney, Australia, April 1998.

39. Graner M., Romney D., He L., Katsanis E. Purification of heat shock and chaperone proteins from A20 murine lymphoma. Presented at the Cold Spring Harbor Meeting on Molecular Chaperones and the Heat Shock Response. Cold Spring Harbor, New York, May 1998.

40. Yorgin P.D., Hartson S.D., Fellah A.M., Scroggins B.T., Huang W., Matts R.L., Katsanis E., Couchman J.M., Whitesell L. Effect of the Hsp90 binding drug geldanamycin on T cell kinases and cellular function. Presented at the Cold Spring Harbor Meeting on Molecular Chaperones and the Heat Shock Response. Cold Spring Harbor, New York, May 1998.

41. Bulte J.W.M, Brooks R.A., Moskowitz B., Verkuyl J.M., Herynek V., Brocke S., Xu S., Jordan E.K., Bryant L.H., Katsanis E., Frank J.A. Antiferromagnetic nanoparticles as contrast agents for magnetoimmunodetection of inflammation-specific adhesion molecules. Presented at the Second International Conference on Scientific and Clinical Applications of Magnetic Carriers, Cleveland, Ohio, May 1998.

42. Graham M.L., Katsanis E., Shapiro T.W., Hutter J.J., Martin P., Kurtzberg J.A. Busulfan and melphalan as preparative therapy for BMT in childhood leukemias. Presented at the American Society of Hematology, Miami, Florida, December 1998. Blood 92(suppl 1):128a, 1998.

43. Perentesis J., DeFor T.E., Neglia J.P., Katsanis E., Ramsay N.K. Successful autologous stem cell transplantation for high-risk pediatric solid tumors. Presented at the American Society of Clinical Oncology, Atlanta, Georgia, May 1999. ASCO Proceedings 18:159, 1999.

44. Katsanis E., Graner M., Raymond A., Akporiaye E. Augmentation of tumor lysate immunogenicity by enrichment of chaperone proteins using free solution isoelectric focusing. Presented at the Keystone Symposia on Cellular Immunity and Immunotherapy of Cancer, Santa Fe, New Mexico, January 2000.

45. Akporiaye E., Mack V., He L., Katsanis E. Tumor-derived transforming growth factor-beta interferes with antigen-presenting functions of bone marrow-derived dendritic cells. Presented at the Keystone Symposia on Cellular Immunity and Immunotherapy of Cancer, Santa Fe, New Mexico, January 2000.

46. Graner M.W., Raymond A., Akporiaye E., Katsanis E. Tumor-derived multiple chaperone enrichment by free solution-isoelectric focusing yields potent anti-tumor vaccines. Presented at the 2nd International Conference on Heat Shock Proteins in Immune Response, Farmington, Connecticut, October 2000. Cell Stress & Chaperones 5:386, 2000.

47. Tyszka E., Davis N., Graner M.W., Katsanis E. Tumor-derived chaperone proteins as anti-cancer vaccines in multiple modality cancer therapy. Presented at the American Association for Cancer Research, New Orleans, Louisiana, March 2001. Proc Am Assoc Cancer Res 42:970, 2001.

48. Zeng Y., Feng H., Whitesell L., Katsanis E. Dendritic cells mature in response to heat stressed apoptotic tumor cells and induce specific immunity in vivo. Presented at the American Association for Cancer Research, New Orleans, Louisiana, March 2001. Proc Am Assoc Cancer Res 42:978, 2001.

49. Feng H., Zeng Y., Ramaiya K., Whitesell L., Katsanis E. Stressed Apoptotic Tumor Cells Express Membrane Heat Shock Proteins and Elicit Tumor Specific Immunity. Presented at the American Association for Cancer Research, New Orleans, Louisiana, March 2001. Proc Am Assoc Cancer Res 42:2725, 2001.

50. Beliakoff J., Katsanis E., Whitesell L. Tyrphostin AG1024-Mediated Inhibition of Cellular Proliferation and Induction of Apoptosis in Neuroblastoma Cells. Presented at the American Association for Cancer Research, New Orleans, Louisiana, March 2001. Proc Am Assoc Cancer Res 42:4576, 2001.

51. Feng H., Zeng Y., Graner M.W., Katsanis E. Exogenous heat shock proteins provide adjuvant effects on enhancing the immunogenicity of apoptotic tumor cells and inducing anti-tumor immunity. Presented at the American Association for Cancer Research, San Francisco, California, April 2002. Proc Am Assoc Cancer Res 43:2214, 2002.

52. Feng H., Zeng Y., Graner M.W., Whitesell L., Katsanis E. Evidence for a novel, caspase 8-independent, Fas death domain-mediated apoptotic pathway. Presented at the American Association for Cancer Research, San Francisco, California, April 2002. Proc Am Assoc Cancer Res 43:3509, 2002.

53. Zeng Y., Feng H., Graner M.W., Katsanis E. Dendritic cells loaded with tumor-derived multiple chaperone proteins enriched by free solution-isoelectric focusing induce significant protective immunity. Presented at the American Association for Cancer Research, San Francisco, California, April 2002. Proc Am Assoc Cancer Res 43:4836, 2002.

54. Graner M.W., Zeng Y., Feng H., Whitesell L., Katsanis E. Tumor-derived multiple chaperone complexes are effective therapeutic vaccines against a variety of cancers. Presented at the Cold Spring Harbor Meeting on Molecular Chaperones and the Heat Shock Response, Cold Spring Harbor, New York, May 2002.

55. Graner M.W., Zeng Y., Feng H., Katsanis E. Leukemia-derived chaperone-rich cell lysates activate dendritic cells and elicit therapeutic immunity against murine leukemia. Presented at the 3rd International Conference on Heat Shock Proteins in Immune Response, Farmington, Connecticut, October 2002.

56. Feng H., Zeng Y., Graner M.W., Likhacheva A., Katsanis E. Exogenous stress proteins enhance the immunogenicity of apoptotic tumor cells and stimulate anti-tumor immunity. Presented at the 17th Meeting of the Society of Biological Therapy, La Jolla, California, November 2002. Journal of Immunotherapy 25:S25, 2002.

57. Graner M.W., Zeng Y., Feng H., Katsanis E. Tumor-derived chaperone-rich cell lysates activate dendritic cells and elicit therapeutic immunity against a wide variety of cancers. Presented at the 17th Meeting of the Society of Biological Therapy, La Jolla, California, November 2002. Journal of Immunotherapy 25:S22, 2002.

58. Katsanis E., Zeng Y., Graner M.W. Leukemia-derived chaperone-rich cell lysates (CRCL) provide bcr-abl specific immunity. Presented at the Keystone Symposia on Basic Aspects of Tumor Immunology, Keystone, Colorado, February 2003.

59. Zeng Y., Graner M.W., Feng H., Katsanis E. Leukemia-derived chaperone-rich cell lysates (CRCL) provide bcr-abl specific immunity. Presented at the American Society of Hematology, San Diego, California December 2003. Blood 102:655a, 2003.

60. Zeng Y., Graner M.W., Feng H., Li G., Katsanis E. Imatinib mesylate effectively combines with chaperone-rich cell lysate loaded dendritic cells to treat bcr-abl+ murine leukemia. Blood 102:322b, 2003.

61. Davis J.M., Romanoski M.A., Likhacheva A., Raymond A., Brandenberger J., Graner M.W., Katsanis E. The immunosuppressive effects and biochemistry of tumor expressed albumin. Presented at the American Association for Cancer Research Meeting, Orlando, Florida, March 2004. Proc Am Assoc Cancer Res 45:2172, 2004.

62. Kislin K. L., Graner M.W., Katsanis E. Peptide-loaded chaperone-rich cell lysates may enhance the effectiveness of anti-cancer vaccines. Presented at the American Association for Cancer Research, Orlando, Florida, March 2004. Proc Am Assoc Cancer Res 45:5457, 2004.

63. Akporiaye E., Ramanathapuram L., Kobie J.J., Katsanis E., Graner M. Cytoreduction and immunostimulation: Properties of α-tocopheryl succinate that enhance the effectiveness of dendritic cells in treating established murine lung cancer. Presented at the American Institute for Cancer Research, Washington DC, July 2004. Journal of Nutrition 134 (12): 3545s-3545s Suppl. S, 2004.

64. Li G., Zeng Y., Chen X., Sepassi M., Romanoski M.A., Thompson S., Graner M.W., Brewer M.A., Katsanis E. Human ovarian tumor-derived chaperone-rich cell lysates (CRCL) activate dendritic cells and elicit T cell responses in vitro. Presented at the 19th Meeting of the Society of Biological Therapy, San Francisco, California, December 2004. Journal of Immunotherapy 27 (6): S26-S27 2004.

65. Chen X., Zeng Y., Li G., Thompson S., Sepassi M., Romanoski M.A., Graner M.W., Katsanis E. Tumor-derived chaperone-rich cell lysate (CRCL) can be effectively combined with syngeneic bone marrow transplantation to treat bcr-abl$^+$ leukemia in a murine model. Presented at the American Society of Hematology, San Diego, California, December 2004. Blood 104:811a, 2004.

66. Zeng Y., Cai X., Larmonier N., Katsanis E. Chaperone Rich Cell Lysates (CRCL) activate innate immune responses. Presented at the Keystone Symposia on Inflammation and Cancer, Breckenridge, Colorado, February 2005.

67. Larmonier N., Zeng Y., Marron M., Thompson S., Katsanis E. Role of CD4$^+$CD25$^+$ regulatory T cells in the immune response to chaperone rich cell lysate (CRCL) -based vaccination against a BCR-ABL$^+$ leukemia. Presented at the Keystone Symposia on Basic Aspects of Tumor Immunology, Keystone, Colorado, March 2005.

68. Cai X., Zeng Y., Marron M., Katsanis E. Tumor-derived chaperone rich cell lysates (CRCL) activate the innate immune system. Presented at the American Association for Cancer Research Meeting, Anaheim, California, April 2005. Proc Am Assoc Cancer Res 46:6048, 2005.

69. Kislin K.L., Graner M.W., Marron M.T., Katsanis E. Chaperone-rich cell lysate (CRCL) possesses a high carrying capacity for antigenic peptides leading to enhanced CTL activation. Presented at the American Association for Cancer Research Meeting, Anaheim, California, April 2005. Proc Am Assoc Cancer Res 46:5169, 2005.

70. Bleifuss E., Thompson S., Milani V., Graner M, Noessner E., Katsanis E., Issels R. Chaperone rich cell lysates (CRCL) as human anti tumour vaccines. Presented at the 22nd meeting of the European Society for Hyperthermic Oncology, Graz, Austria, June 2005.

71. Andreansky S., Li G., Sepassi M., Katsanis E. A multi-chaperoned heat shock protein based tumor vaccine can generate humoral immunity in a HER-2/neu specific mouse tumor model. Presented at the Sixth Arizona Biosciences Research Symposium, Phoenix, Arizona, June 2006.

72. Cantrell J., Cai X., Zeng Y., Larmonier N., Katsanis E. Adjuvant Effect of CRCL: Activation of dendritic cells and macrophages. Presented at the Sixth Arizona Biosciences Research Symposium, Phoenix, Arizona, June 2006.

73. Kislin K.L., Graner M.W., Li G., Marron M., Katsanis E. Chaperone-Rich Cell Lysate embedded with exogenous peptides demonstrates enhanced anti-tumor activity. Presented at the Sixth Arizona Biosciences Research Symposium, Phoenix, Arizona, June 2006.

74. Larmonier N., Cantrell J., Katsanis E. Modulation of regulatory T lymphocyte-induced suppression of antigen presenting cells by tumor cell lysates enriched in chaperone proteins. Presented at the AACR Special Conference, Tumor Immunology: an integrated perspective, Miami, Florida, November 2006.

75. Li G., Andreansky S., Chen X., Penichet M., Katsanis E. Tumor-derived Chaperone-Rich Cell Lysate generates HER-2/neu specific immunity in a mouse model of breast cancer. Presented at the American Association for Cancer Research Meeting, Los Angeles, California, April 2007. Proc Am Assoc Cancer Res 48: LB-337, 2007.

76. Fiederlein R., Salamon D., Berg M.P., Katsanis E., Graham M. Assessment of cell recovery obtained from cord blood units from different banks following thawing and cell washing. Presented at the American Association of Blood Banks Meeting, Anaheim, California, October 2007.

77. Graham ML., Andreansky M., Katsanis E., Wood T.S., Hutter J.J. Busulfan and single-dose melphalan as preparative therapy for infants and young children undergoing stem cell transplantation for leukemia: A single center experience. Biology of Blood and Marrow Transplantation 14:87-88, Suppl. 2. # 236 February 2008

78. Fraszczak J., Trad M., Dominique C., Janikashvili N., Katsanis E., Bonnotte B., and Larmonier N. Peroxynitrite-dependent killing of cancer cells and presentation of released tumor antigens by activated dendritic cells. Club Francophone des Cellules Dendritiques, Paris, France, March 2009.

79. Situ E., Katsanis E., Larmonier N. Influence of imatinib mesylate on bone marrow-derived dendritic cells. Journal Of Investigative Medicine. Volume: 58 Issue: 1 Page: 193, #313, Jan 2010.

80. Wright J., Larmonier N., Katsanis E. Conversion inhibition of naive T lymphocytes into regulatory T cells by killer dentritic cells. Journal Of Investigative Medicine. Volume: 58 Issue: 1 Page: 216, #395, Jan 2010.

81. LaCasse C.J., Janikashvili N., Katsanis E., Larmonier N. Th-1 lymphocytes promote dendritic cell tumoricidal activity. AACR Tumor Immunology: Basic and Clinical Advances conference. Miami, Florida December 2010.

GRANT SUPPORT

Federal Government

Medical Research Council of Canada Fellowship
Identification of mechanisms of immunosuppression
7/1/89 - 6/30/91
Total Direct Costs: $80,000
PI: Katsanis (100%)

NIH P01 CA21737
Autologous bone marrow transplantation for lymphoma: Immunotherapeutic studies
3/1/92-12/31/96
Total Direct Costs: $520,000
PI: Kersey, PI Project #3: Weisdorf, Co-PI Project #3 Katsanis (15%)

Department of Defense DAMD17-03-1-0208
Chronic Myelogenous Leukemia Research Program
Chaperone rich cell lysate (CRCL) vaccine for chronic myelogenous leukemia
5/22/03 - 5/21/06 relinquished 2/29/04 due to funding of NIH R01 CA104926
Total Direct Costs: $483,501
PI: Katsanis (25%)

NIH R21 CA102410
Multiple chaperone complexes: Natural adjuvants and antigens for dendritic cell based vaccines
7/1/03 - 6/30/06
Total Direct Costs: $300,000
PI: Katsanis (20%)

NIH R01 CA104926-1
Chaperone rich cell lysate (CRCL) vaccine for chronic myelogenous leukemia
3/1/04 - 2/29/09
Total Direct Costs: $738,000
PI: Katsanis (25%)

NIH K23 CA107450
Hsp90 as a target for the treatment of childhood cancer
9/1/06-8/31/11
Total Direct Costs: $552,500
PI: R. Bagatell, Primary Mentor: Katsanis

NIH R01 CA104926-5
Immunotherapy for chronic myelogenous leukemia
7/1/09 - 4/30/14
Total Direct Costs: $900,935
PI: Katsanis (25%)

NIH R01 NR010889
Childhood leukemia: Oxidative stress, cognitive changes & academic outcomes
6/1/09 - 3/31/14
Total Direct Costs: $2,089,367
PI: Moore, Co-investigator: Katsanis (5%)

NIH K08 AR054323
Characterization of pathogenic Th17 responses in collagen induced arthritis
7/1/09-6/30/14
Total Direct Costs: $587,500
PI: S. Sarkar, Primary Mentor:Katsanis

GRANT SUPPORT

State Government

Arizona Disease Control Research Commission
Improvement of anticancer immune responses generated by chaperone protein associated tumor peptides
7/1/99 - 6/30/01
Total Direct Costs: $392,791
PI: Katsanis

Arizona Disease Control Research Commission
Development of antisense oligonucleotides as chemotherapeutic agents for intratumoral administration7/1/99 - 6/30/01
Total Direct Costs: $383,032
PI: Whitesell, Co-Investigator: Katsanis

Arizona Disease Control Research Commission
Heat shock proteins as targets for drug discovery
7/1/01 - 6/30/03
Total Direct Costs: $367,236
PI: Whitesell, Co-Investigator: Katsanis

Arizona Disease Control Research Commission (#8-028)
Chaperone rich cell lysate vaccine for ovarian cancer
7/1/03 - 6/30/06
Total Direct Costs: $273, 828
PI: Katsanis

GRANT SUPPORT

National Private Foundations

Canadian Cancer Society Fellowship, Gordon E. Richard Award
Treatment of pediatric cancers
7/1/86 - 6/30/87
Total Direct Costs: $34,440
PI: Katsanis

Ronald McDonald Children's Charities
Use of immunochemotherapeutic agents against murine neuroblastoma
10/1/91 - 9/30/92
Total Direct Costs: $17,350
PI: Katsanis

American Cancer Society Clinical Oncology Career Development Award 93-30,
Generation of a specific immune response against neuroblastoma
7/1/93 - 6/30/96
Total Direct Costs: $90,000
PI: Katsanis (50%)

Cancer Research Foundation of America
Development of anti-tumor vaccines for neuroblastoma
10/1/94 - 9/30/95
Total Direct Costs: $30,000
PI: Katsanis

Concern Foundation for Cancer Research
Induction of antitumor immunity against neuroblastoma by gene modified antigen presenting cells
1/1/96 - 6/30/98
Total Direct Costs: $35,120
PI: Katsanis

American Cancer Society IM-785
Augmentation of anti-tumor T cell responses by GM-CSF activated antigen presenting cells 1/1/96 - 12/31/99
Total Direct Costs: $255,200
PI: Katsanis (25%)

W.M. Keck Foundation
Development of tumor-specific immunity in transgenic mice
7/1/98 - 6/30/01
Total Direct Costs: $165,000
PI of project #4: Katsanis

Leukemia and Lymphoma Society,Translational Research Grant
Analysis of T cell response to the bcr/abl gene product
12/31/98-12/30/02
Total Direct Costs: $300,000
PI: Katsanis (20%)

Leukemia and Lymphoma Society Fellow Award
Modulation of regulatory T cell suppressive activity by chaperone rich cell lysate
7/1/06-6/28/09
Total Direct Costs: $141,000
PI: Larmonier, Primary Mentor: Katsanis

America Cancer Society, Mentored Research Scholars Grant
A multiepitope heat shock protein based tumor vaccine against HER-2 cancers
1/1/08-12/31/12
Total Direct Costs: $585,000
PI: S. Andreansky, Primary Mentor: Katsanis

Alex's Lemonade Stand Foundation for Childhood Cancer Young Investigator Award
Reciprocal interactions between tumor killer DC and tumor-induced Treg
7/1/08-6/30/10
Total Direct Costs: $80,000
PI: Larmonier, Primary Mentor: Katsanis

PATENTS

Methods of recovering chaperone proteins and complexes thereof
Patent Filed: March 5, 2002,
Approved: April 5, 2005
U.S. Patent No. 6,875,849

Vaccine compositions and methods
Patent Filed: May 5, 2008
Serial No. 61/050,294

PRESENTATIONS (2000-present)

- Translational Research Progress Report Meeting, The Leukemia and Lymphoma Society, Washington, DC, Analysis of T cell response to the bcr/abl gene product, 2000
- Cancer Vaccines Workshop, Tucson, Arizona, Dendritic cell based vaccines, 2000
- Department of Pediatrics Research Conference, Steele Children's Research Center, Auto-focused vaccine against cancer, 2001
- Immuno-Designed Molecules (IDM) Inc, Paris, France, Stress proteins and anti-tumor responses, 2001
- Grand Rounds, Phoenix Children's Hospital, Phoenix, Arizona, Biologic therapy of cancer, 2001
- Arizona Cancer Center Retreat, Westin La Paloma, Tucson, Arizona, Multiple chaperone complexes: The new wave of anticancer vaccines, 2002
- American Society for Clinical Laboratory Science, Arizona/Nevada Division Symposium Southern Arizona Veteran's Administration Hospital, Tucson, Arizona, New immunobiologic approaches for cancer, 2002
- Pediatric Grand Rounds, University Medical Center, The top ten Hem/Onc list for the pediatrician, 2002
- Pediatric Specialty Conference, Childhood leukemia, 2002
- 4th Annual Immunobiology of Cancer Workshop, Tucson, Arizona, Tumor-derived multiple chaperone complexes are effective therapeutic vaccines, 2002
- Earle A. Chiles Research Institute, Portland, Oregon, Tumor derived chaperone rich cell lysates: Effective adjuvants and antigens for cancer, Immunotherapy, 2003
- Pediatrics Club Meeting, University of Arizona Medical School, Introduction to Pediatric Cancer, 2003
- Women's Cancers Scientific Retreat, Tucson, Arizona, Ovarian tumor-derived chaperone-rich cell lysates elicit T cell responses in vitro, 2005
- Grand Rounds, Phoenix Children's Hospital, Phoenix, Arizona, The hematologic response to systemic illness in children, 2005
- Obstetrics and Gynecology, Grand Rounds, University of Arizona Health Sciences Center, Tumor-Derived Chaperone-Rich Cell Lysate (CRCL) is an effective autologous vaccine with potential applications against gynecologic malignancies, 2005
- Ovarian Cancer Forum, Tucson, Arizona, Ovarian cancer vaccine: fact or fiction, 2006
- Frontiers in Immunobiology and Immunopathogenesis, Hilton El Conquistador, Oro Valley, Arizona, Chaperone rich cell lysate: Antigen, Adjuvant, Activator, 2006
- Department of Pediatrics Research Conference, Steele Children's Research Center, CRCL Vaccine: Closing the Circle on Cancer, 2006
- Pediatric Specialty Conference, Solid progress against pediatric liquid tumors, 2006
- Pediatric Grand Rounds, The blood's response to pediatric diseases, 2006
- Frontiers in Medical Research Seminar, College of Medicine, Heat shock proteins as anticancer vaccines, 2006

- The Biodesign Institute, Arizona State University, Tempe, Arizona, CRCL Vaccine: Closing the Circle on Cancer, 2006
- Pediatric Specialty Conference, Leukemia, 2008
- Conversations with Colleagues, Finding your scholarship, University of Arizona Health Sciences Center, 2008
- Pediatric Specialty Conference, Thrombocytopenias, 2009
- Caring for the Seriously Ill: Clinical Updates in Oncology Symposium, Arizona Cancer Center, Pediatric Leukemia, 2009
- Frontiers in Medical Research Seminar, College of Medicine, Tumor Immunology, 2009
- Pediatric Specialty Conference, BMT emergencies, 2010
- Pediatric Specialty Conference, Bone marrow failure, 2010
- Pediatric Grand Rounds, Acute Myelogenous Leukemia; chemotherapy and beyond, 2010
- Pediatric Hematology/Oncology/BMT Clinical Lecture Series, Overview of stem cell transplantation, 2010

MENTORING ACTIVITIES (University of Arizona)

Junior Faculty Mentor

Nicolas Larmonier, Ph.D., Research Assistant Professor Pediatrics, 7/06-6/09, LLS Fellow
Rochelle Bagatell, M.D., Associate Professor Pediatrics, 9/06-8/11, NIH K23 award
Samita Andreansky, Ph.D., Res. Assistant Prof, 1/08-12/12, ACS Mentored Research Scholar
Sujata Sarkar, M.D., Assistant Professor Medicine 7/09- NIH K08 award

Junior Faculty Research Committees

Nicolas Larmonier, Ph.D., Habilitation à Diriger des Recherches, Université de Bourgogne, 2008

Postgraduate Level Mentor

Adnan Sarcevic, M.D., M.S. 4/97 - 10/97 ⇨ Resident, SUNY at Stony Brook
Lin He, M.D., M.S. 7/97 - 12/99 ⇨ Post-Doc, Northwestern University
Michael Graner, Ph.D. 8/97 - 6/04 ⇨ Research Associate Professor, Duke University
Yi Zeng, M.D., Ph.D. 8/03 – 5/06 ⇨ Resident Pediatrics, Indiana University
Nicolas Larmonier, Ph.D. 8/04 – 12/06 ⇨ Research Assistant Professor, University of Arizona
Nona Janikashvili, Ph.D. 1/07 – 3/10 ⇨ Post-Doc, Université de Bourgogne
Gang Li, Ph.D., 3/07 – 8/08 ⇨ Post-Doc, University of Arizona
Raquel Bravo, M.D., 7/09- present

Graduate Level Mentor

Hanping Feng, Ph.D. Immunology, 2/99 - 7/02 ⇨ Post-Doc, Harvard Medical School
Yi Zeng, M.D., Ph.D. Immunology, 9/99 - 8/03 ⇨ Post-Doc, University of Arizona
Xinchun Chen, M.D., Ph.D. Immunology, 8/02 – 11/06 ⇨ Associate Professor, Shenzhen, China
Kerri Kislin, Ph.D., Cancer Biology, 3/03 – 9/06 ⇨ Translational Genomics Research Institute
Gang Li, Ph.D., Immunology, 8/02 – 3/07⇨ Post-Doc, University of Arizona
Jessica Cantrell, Ph.D., Cancer Biology, 7/05 – 5/09 ⇨ U. of Colorado, C. of Veterinary Medicine
Collin J. LaCasse, Immunobiology, 12/06- present
Tamara Lundeen, M.S. Immunobiology, 8/08 – 8/09 withdrew⇨ Medical School, U. of Arizona
Sara Bustamante, Cancer Biology, 4/08 - present
Neale Hanke, Cancer Biology 3/10- present
Darya Alizadeh, Cancer Biology 2/11- present
Alexis Bucknam, Immunobiology 2/11 - present

Graduate Level Supervisory Committees (not primary mentor)

John Richards, Ph.D. Immunology, 1998 - 2002
James Kobie, Ph.D. Immunology, 1999 - 2003
Tong Zhang, Ph.D. Immunology, 1999 - 2003
Vivian Mack, M.S. Immunology, 1999 - 2004
Lalitha Ramanathapuram, Ph.D. Immunology 2002 - 2006
Naihsuan Guy, M.S. Immunobiology, 2005 - 2006
Matthew Rausch, Ph.D. Immunobiology, 2005 - 2009
Maria Ordaz, M.S. Immunobiology, 2006 - 2009
Lora Grainger, Ph.D. Immunobiology, 2006 - 2010
Claire Larmonier, Ph.D. Immunobiology, 2007 – 2010

Graduate Level (laboratory Rotations)

Suzanne Stratton, Cancer Biology 9/97 - 12/97
Manolis Demetriou, Cancer Biology 9/99 - 12/99
Elizabeth Tyszka, Cancer Biology 8/00 - 12/00
Michael DeNiro, Cancer Biology 5/02 - 7/02
Maria Ordaz, Immunobiology 4/05 - 9/05
Mark Teng, Cancer Biology 1/08 - 4/08
Rajalakshmy Ramalingam, Immunobiology 4/08 - 6/08

Undergraduate Level Mentor

Davis Romney, 11/97 - 5/98, ⇨ Medical School, University of Virginia
Amber Kyle, 5/99 - 12/99, ⇨ Medical School, University of Michigan
Nicole Davis, 5/98 - 12/99, ⇨ School of Public Health, Drexel University
Hector Sandoval, 6/99 - 5/00, ⇨ Graduate School, Baylor University
Amy Raymond, 1/99 - 6/00, ⇨ Graduate School, UC San Diego
Susan Hoy, 11/98 - 12/00, ⇨ Graduate School, University of Colorado
Kamalesh Ramaiya, 5/99 - 5/01, ⇨ Medical School, University of Arizona
Jared Brandenberger, 6/00 - 5/02, ⇨ Medical School, University of Arizona
Anna Likhacheva, 5/00 - 5/03, ⇨ Medical School, University of Arizona
Jane Davis, 5/02 - 5/04, ⇨ Medical School, University of Arizona
Sylvia Thompson, 5/03 - 4/05, ⇨ Medical School, University of Arizona
M. Angela Romanoski, 5/03 - 7/05, ⇨ Medical School, University of Arizona
Xuemei Cai, 2/03 - 7/05, ⇨ Medical School, Harvard University
Marjan Sepassi, 3/04 - 8/07, ⇨ School of Pharmacy, University of Arizona
Elaine Situ, 8/06 – 5/09 ⇨ Medical School, University of Arizona
Amanda Herrell, 1/08 – 5/10 ⇨ Peace Corps
Andres Longoria, 10/09 - 8/10 ⇨ Medical School, University of Arizona
Leila Amini, 9/10 -

Minority Health Disparities Summer Research Program

Irene Adu-Gyamfi, 6/06 - 8/06

Minority Research Training Program

Bradley Bowman, 6/09 - 8/09

Medical Student Research Program

Jason Wright, 5/08 - 7/10

Medical Students

Elaine Situ, 5/09 - present
Joseph Chao, 2/11 - present

Pediatric Resident Clinical Advisor

Alejandro de la Torre, M.D., 7/04 – 6/07
Nathan Price, M.D., 7-07 – 6/08
Kiran Kulkarni, M.D., 7-08 - present

TEACHING ACTIVITIES (2000-present)

Graduate School Courses

Clinical Cancer Biology CBIO 561, **Course Director, 2008- present**
- Participating Faculty, Clinic Shadowing in Pediatric Oncology, 2004-present
- Neuroblastoma, 2008
- Pediatric Leukemia, 2009
- Hematopoietic stem cell transplantation, 2011

Cancer Therapeutics CBIO 555,
- Cancer Immunotherapy, 2009

Cancer Immunology and Immunotherapy CBIO 565
- Cytokines & adoptive cell transfer, 2010
- Bone marrow transplantation, 2010
- Cancer vaccines, 2010

Advanced Topics in Immunobiology IMB564
- Cancer Immunotherapy, 2011

Medical School Courses

Medical Microbiology/Immunology 801/501 (Facilitator, Clinical correlates)
- Lymphoma, 2000
- Autoimmunity, 2000
- Transplantation, 2000
- Transplantation, 2001

Dean's Rounds (Facilitator)
- Cultural competency and the cross-cultural interview, 2004

Cancer Block (AZ Med)
- Pediatric Leukemias, 2008
- Pediatric Leukemias, 2009
- Anemia, 2009
- Acute Lymphoblastic Leukemia CBI Case Conference, 2009

Advance Topics Block (AZ Med)
- Anemia, 2010
- Acute Leukemia, 2010
- Acute Lymphoblastic Leukemia CBI Case Conference, 2010

Resident Teaching Conferences

Pediatric stem cell transplantation: an overview, 2001
Cancer chemotherapy, 2001
Supportive care for the pediatric oncology patient, 2001
Blood transfusions, 2002
Oncologic emergencies, 2002
Childhood leukemias, 2002
Diagnostic approach to the child with anemia, 2003
Acute lymphoblastic leukemia, 2004
Bleeding disorders in children, 2005
Childhood leukemias, 2006
Pediatric lymphomas, 2006
Supportive care for children with cancer, 2007

Nursing Teaching Conferences

Infections following stem cell transplantation, 2000
Acute lymphoblastic leukemia, 2006
Tumor lysis syndrome, 2006

Clinical Teaching

Medical Student Attending, General Pediatrics (3 wk/yr), 1997- 2009
Pediatric Residents and Medical Students: Ward team and electives 1997-present

COMMITTEE & ADMINISTRATIVE ACTIVITIES *denotes active

National – International

Organizing committee, Annual Meeting of the International Society for Experimental Hematology, 1994

University

Faculty Council, University of Ottawa, 1983-84
Transfusion Sub-Committee, University of Ottawa, 1984-87
Frontiers in Immunobiology and Immunopathogenesis Symposium Planning Committee, 2005-08
Chairman, Committee for Review of the Head of the Dept. of Pediatrics, U. of AZ, 2006-07
Founders Day Selection Committee, U. of Arizona, College of Medicine, 2009
Promotion and Tenure Committee, U. of Arizona, College of Medicine, 2008-2010
* Endowed Chair Committee, U. of Arizona, College of Medicine, 2009-present
* M.D.-Ph.D. Program Advisory Committee, U. of Arizona, College of Medicine, 2010-present

Centers

* Blood and Marrow Transplantation Committee, Arizona Cancer Center, 1997-present
Immunobiology Core Committee, Arizona Cancer Center, 1999-04
Stem Cell Transplantation M&M Committee, Arizona Cancer Center, 2004-05
Experimental Mouse Shared Service Committee, Arizona Cancer Center, 2004-05
* Arizona Cancer Center Director's Committee, 2006-present
* Arizona Cancer Center Clinical Operations Executive Committee, 2008 – present
* Arizona Cancer Center - Phoenix Campus Executive Architect Committee, 2010 – present

Departments

Pediatric Bone Marrow Transplantation Committee, U of Minnesota, 1991-97
Faculty Development Committee, Dept. of Pediatrics, U. of Arizona, 1998-02
Computer Committee, Dept. of Pediatrics, U. of Arizona, 1998-02
Director of Transfusion Medicine Search Committee, Dept. of Pathology, U. of Arizona, 2001
Space Committee, Dept. of Pediatrics, U. of Arizona, 2008-10
Faculty Recruitment Search Committee, Dept. of Immunobiology, 2008 – 10
* Clinical Steering Committee, Dept. of Pediatrics, U. of Arizona, 2004 - present
* Promotion and Evaluation Committee, Dept. of Immunobiology, 2007- present
* Executive Committee, Dept. of Pediatrics, U. of Arizona, 2011-present

Graduate Programs

Interviewer, Interdisciplinary Graduate Program in Cancer Biology, U. of Arizona, 2005-07
Admissions Committee, Dept. of Immunobiology Graduate Program, U. of Arizona, 2005-08
Executive Committee, Immunobiology Graduate Program, U. of Arizona, 2007- 2010
* Executive Committee, Cancer Biology Graduate Interdisciplinary Program , U. of Arizona, 2007-present
* Admissions Committee, Cancer Biology Graduate Interdisciplinary Program, U. of Arizona, 2007-present
* NIH T32 Training Grant Selection Committee, Cancer Biology Graduate Interdisciplinary Program, U. of Arizona, 2010-present
* Curriculum Committee, Cancer Biology Graduate Interdisciplinary Program , U. of Arizona, 2010-present

OTHER SERVICE

Interviewer, Department of Pediatrics Residency Program, University of Arizona, 1998-present
Interviewer, College of Medicine Admissions, University of Arizona, 1999- 2008
Interviewer, Department of Surgery, Faculty Recruitment, 2007-2008

CLINICAL ACTIVITIES

Attending Physician, Pediatric BMT, U. of Minnesota, 1991-1997
Attending Physician, Pediatric Hem-Onc-BMT, U. of Arizona, 1997- present
Medical Director, Blood and Marrow Transplant Laboratory, University Medical Center, 1999-present
Medical Director, Pediatric Oncology, University Medical Center, 2008-present
Medical Director, Pediatric BMT, University Medical Center, 2010-present